title: Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy.
authors.affiliation: M.D. Anderson Cancer Center, Houston, TX, USA. jlmunoz@mdanderson.org
authors.forename: Javier
authors.initials: J
authors.lastname: Munoz
authors.forename: David
authors.initials: D
authors.lastname: Hong
authors.forename: Razelle
authors.initials: R
authors.lastname: Kurzrock
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D000068818:Cetuximab; D003875:Drug Eruptions / Q000503:physiopathology; D004347:Drug Interactions; D000069347:Erlotinib Hydrochloride; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000503:physiopathology; D006406:Hematoma / Q000139:chemically induced / Q000503:physiopathology; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012720:Severity of Illness Index; D020246:Venous Thrombosis / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000970:Antineoplastic Agents; D006495:Heparin, Low-Molecular-Weight; D011799:Quinazolines; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; D000068818:Cetuximab